<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25927214</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1478-6362</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>27</Day></PubDate></JournalIssue><Title>Arthritis research &amp; therapy</Title><ISOAbbreviation>Arthritis Res Ther</ISOAbbreviation></Journal><ArticleTitle>Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up.</ArticleTitle><Pagination><StartPage>109</StartPage><MedlinePgn>109</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">109</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13075-015-0614-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Renal involvement is a severe complication in systemic lupus erythematosus (SLE). Moreover, a subset of SLE patients develop the anti-phospholipid syndrome (APS), characterised by the occurrence of anti-phospholipid antibodies in combination with macro- and microvascular thrombotic manifestations, including acute and chronic antiphospholipid-associated nephropathy (APLN). Clinical presentations of lupus nephritis and APLN are similar and a renal biopsy is necessary to differentiate between the conditions. Our aim with this study was to investigate the occurrence of histopathological findings consistent with APLN (hAPLN) in renal biopsies from SLE patients and to investigate associations with anti-phospholipid antibody specificities, clinical manifestations, HLA-DRB1 alleles, and long-term renal outcome.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Consecutive renal biopsies from 112 SLE patients with renal involvement were investigated and evaluated for findings of hAPLN; in all there were 236 renal biopsies. Data from biopsy reports and clinical information were collected. Autoantibodies against cardiolipin and &#x3b2;2-glycoprotein-1 were measured by enzyme-linked immunosorbent assay. A lupus anticoagulant test was determined with a modified Dilute Russel Viper Venom method. HLA genotyping was performed by sequence-specific primer PCR. Renal outcome was determined at study end.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence of hAPLN was 14.3% among SLE patients with renal involvement. Compared to patients with pure lupus nephritis, occurrence of hAPLN was associated with intima changes (odds ratio (OR) = 24; 95% confidence interval (CI), 3.0 to 189.8; P &lt; 0.0001), hypertensive vascular changes (OR = 7.8; 95% CI, 1.6 to 39.4; P = 0.01), inflammatory infiltrates (OR = 6.5; 95% CI, 1.7 to 25.1; P = 0.007) and tubular atrophy (OR = 13.1; 95% CI, 1.7 to 103.6; P = 0.002). hAPLN was associated with the presence of cardiolipin antibodies (OR = 3.3; 95% CI, 1.0 to 10.8; P = 0.05) and triple anti-phospholipid antibody positivity (OR = 4.2; 95% CI, 1.3 to 13.7; P = 0.02). Patients with hAPLN were more hypertensive (OR = 3.8; 95% CI, 1.2 to 12.3; P = 0.03) and had higher levels of creatinine as compared to lupus nephritis patients (median 116 versus 75 &#x3bc;mol/L; P &lt; 0.0001). We found significantly higher frequency of HLA-DRB1*13 (OR = 5.1; 95% CI, 1.7 to 15.4; P = 0.03) and development of end-stage renal disease (OR = 5.8; 95% CI, 1.7 to 19.7; P = 0.008) in hAPLN compared with lupus nephritis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">hAPLN is a severe and often unrecognized condition in SLE patients with renal involvement. We have demonstrated an increased risk for development of renal impairment and a genetic predisposition in hAPLN patients compared to lupus nephritis patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gerhardsson</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Unit of Rheumatology, Karolinska University Hospital, Karolinska Institutet, S-171 76, Stockholm, Sweden. jakob.gerhardsson@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundelin</LastName><ForeName>Birgitta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cytology, Karolinska University Hospital, Karolinska Institutet, S-171 76, Stockholm, Sweden. birgitta.sundelin-vonfeilitzen@karolinska.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zickert</LastName><ForeName>Agneta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Unit of Rheumatology, Karolinska University Hospital, Karolinska Institutet, S-171 76, Stockholm, Sweden. agneta.zickert@karolinska.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padyukov</LastName><ForeName>Leonid</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine, Unit of Rheumatology, Karolinska University Hospital, Karolinska Institutet, S-171 76, Stockholm, Sweden. leonid.padyukov@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svenungsson</LastName><ForeName>Elisabet</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine, Unit of Rheumatology, Karolinska University Hospital, Karolinska Institutet, S-171 76, Stockholm, Sweden. elisabet.svenungsson@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunnarsson</LastName><ForeName>Iva</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Medicine, Unit of Rheumatology, Karolinska University Hospital, Karolinska Institutet, S-171 76, Stockholm, Sweden. iva.gunnarsson@karolinska.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arthritis Res Ther</MedlineTA><NlmUniqueID>101154438</NlmUniqueID><ISSNLinking>1478-6354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059811">HLA-DRB1 Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506473">HLA-DRB1*13 antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="N">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059811" MajorTopicYN="N">HLA-DRB1 Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="N">Lupus Nephritis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25927214</ArticleId><ArticleId IdType="pmc">PMC4443508</ArticleId><ArticleId IdType="doi">10.1186/s13075-015-0614-5</ArticleId><ArticleId IdType="pii">10.1186/s13075-015-0614-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vikerfors A, Johansson AB, Gustafsson JT, Jonsen A, Leonard D, Zickert A, et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology. 2013;52:501&#x2013;9. doi: 10.1093/rheumatology/kes252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes252</ArticleId><ArticleId IdType="pubmed">23159889</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus. 2010;19:419&#x2013;23. doi: 10.1177/0961203309360541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309360541</ArticleId><ArticleId IdType="pubmed">20353980</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost. 2006;4:295&#x2013;306. doi: 10.1111/j.1538-7836.2006.01753.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 2004;50:2569&#x2013;79. doi: 10.1002/art.20433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20433</ArticleId><ArticleId IdType="pubmed">15334471</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Chen Y, Ao W, Shen Y, Chen XW, Dai M, et al. Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases. Arthritis Res Ther. 2009;11:R93. doi: 10.1186/ar2736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2736</ArticleId><ArticleId IdType="pmc">PMC2714149</ArticleId><ArticleId IdType="pubmed">19545416</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugas E, Nochy D, Huong DL, Duhaut P, Beaufils H, Caudwell V, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol. 2002;13:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">11752020</ArticleId></ArticleIdList></Reference><Reference><Citation>Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15:R12. doi: 10.1186/ar4142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4142</ArticleId><ArticleId IdType="pmc">PMC3672792</ArticleId><ArticleId IdType="pubmed">23320601</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes GR. The antiphospholipid syndrome. Lupus. 1996;5:345&#x2013;6. doi: 10.1177/096120339600500601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120339600500601</ArticleId><ArticleId IdType="pubmed">8902758</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil HP, Hunt JE, Krilis SA. Antiphospholipid antibodies - new insights into their specificity and clinical importance. Scand J Immunol. 1992;36:647&#x2013;52. doi: 10.1111/j.1365-3083.1992.tb03124.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3083.1992.tb03124.x</ArticleId><ArticleId IdType="pubmed">1439578</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827&#x2013;32. doi: 10.1182/blood-2002-02-0441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2002-02-0441</ArticleId><ArticleId IdType="pubmed">12393574</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolin K, Sandling JK, Zickert A, Jonsen A, Sjowall C, Svenungsson E, et al. Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis. PLoS One. 2013;8 doi: 10.1371/journal.pone.0084450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0084450</ArticleId><ArticleId IdType="pmc">PMC3873995</ArticleId><ArticleId IdType="pubmed">24386384</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundstrom E, Gustafsson JT, Jonsen A, Leonard D, Zickert A, Elvin K, et al. HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis. 2013;72:1018&#x2013;25. doi: 10.1136/annrheumdis-2012-201760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-201760</ArticleId><ArticleId IdType="pubmed">22893315</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeazzi M, Sebastiani GD, Tincani A, Piette JC, Allegri F, Morozzi G, et al. HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus. 2000;9:47&#x2013;55. doi: 10.1177/096120330000900109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120330000900109</ArticleId><ArticleId IdType="pubmed">10715100</ArticleId></ArticleIdList></Reference><Reference><Citation>Svenungsson E, Gustafsson J, Leonard D, Sandling J, Gunnarsson I, Nordmark G, et al. A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis. 2010;69:834&#x2013;40. doi: 10.1136/ard.2009.115535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2009.115535</ArticleId><ArticleId IdType="pubmed">19762360</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271&#x2013;7. doi: 10.1002/art.1780251101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780251101</ArticleId><ArticleId IdType="pubmed">7138600</ArticleId></ArticleIdList></Reference><Reference><Citation>Churg JBJ, Glassock RJ. Renal Disease: Classification and Atlas of Glomerular Diseases. 2. New York: Igaky-Shoin; 1995.</Citation></Reference><Reference><Citation>Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521&#x2013;30. doi: 10.1111/j.1523-1755.2004.00443.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00443.x</ArticleId><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference><Reference><Citation>Nochy D, Daugas E, Droz D, Beaufils H, Grunfeld JP, Piette JC, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol. 1999;10:507&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">10073601</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8:237&#x2013;42. doi: 10.1111/j.1538-7836.2009.03674.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2009.03674.x</ArticleId><ArticleId IdType="pubmed">19874470</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation, Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461&#x2013;70. doi: 10.7326/0003-4819-130-6-199903160-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-130-6-199903160-00002</ArticleId><ArticleId IdType="pubmed">10075613</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int. 2005;67:2089&#x2013;100. doi: 10.1111/j.1523-1755.2005.00365.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2005.00365.x</ArticleId><ArticleId IdType="pubmed">15882252</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths MH, Papadaki L, Neild GH. The renal pathology of primary antiphospholipid syndrome: a distinctive form of endothelial injury. QJM. 2000;93:457&#x2013;67. doi: 10.1093/qjmed/93.7.457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/93.7.457</ArticleId><ArticleId IdType="pubmed">10874055</ArticleId></ArticleIdList></Reference><Reference><Citation>Huong DL, Papo T, Beaufils H, Wechsler B, Bletry O, Baumelou A, et al. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine. 1999;78:148&#x2013;66. doi: 10.1097/00005792-199905000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005792-199905000-00002</ArticleId><ArticleId IdType="pubmed">10352647</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafsson JT, Simard JF, Gunnarsson I, Elvin K, Lundberg IE, Hansson LO, et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther. 2012;14:R46. doi: 10.1186/ar3759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3759</ArticleId><ArticleId IdType="pmc">PMC4060356</ArticleId><ArticleId IdType="pubmed">22390680</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafsson J, Gunnarsson I, Borjesson O, Pettersson S, Moller S, Fei GZ, et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res Ther. 2009;11:R186. doi: 10.1186/ar2878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2878</ArticleId><ArticleId IdType="pmc">PMC3003532</ArticleId><ArticleId IdType="pubmed">20003285</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>